• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Alpha Cognition Inc.

    1/31/25 6:17:18 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Alpha Cognition Inc.

    (Name of Issuer)


    Common Shares, no par value

    (Title of Class of Securities)


    02074J501

    (CUSIP Number)


    01/15/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    02074J501


    1Names of Reporting Persons

    BESSER JAMES E
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    210,000.00
    6Shared Voting Power

    793,203.00
    7Sole Dispositive Power

    210,000.00
    8Shared Dispositive Power

    793,203.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,003,203.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    02074J501


    1Names of Reporting Persons

    FRANK MORGAN C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    45,000.00
    6Shared Voting Power

    776,181.00
    7Sole Dispositive Power

    45,000.00
    8Shared Dispositive Power

    776,181.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    821,181.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Alpha Cognition Inc.
    (b)Address of issuer's principal executive offices:

    1200 - 750 West Pender Street, Vancouver, British Columbia V6C
    Item 2. 
    (a)Name of person filing:

    James E. Besser Morgan C. Frank
    (b)Address or principal business office or, if none, residence:

    James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America Morgan C. Frank c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America
    (c)Citizenship:

    James E. Besser - United States of America Morgan C. Frank - United States of America
    (d)Title of class of securities:

    Common Shares, no par value
    (e)CUSIP No.:

    02074J501
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    James E. Besser - 1,003,203 Morgan C. Frank - 821,181
    (b)Percent of class:

    James E. Besser - 6.2% Morgan C. Frank - 5.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    James E. Besser - 210,000 Morgan C. Frank - 45,000

     (ii) Shared power to vote or to direct the vote:

    James E. Besser - 793,203 Morgan C. Frank - 776,181

     (iii) Sole power to dispose or to direct the disposition of:

    James E. Besser - 210,000 Morgan C. Frank - 45,000

     (iv) Shared power to dispose or to direct the disposition of:

    James E. Besser - 793,203 Morgan C. Frank - 776,181

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G that are not directly owned by James E. Besser and Morgan C. Frank, are directly owned by advisory clients of management entities controlled by James E. Besser. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Shares, no par value.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BESSER JAMES E
     
    Signature:/s/ James E. Besser
    Name/Title:James E. Besser
    Date:01/31/2025
     
    FRANK MORGAN C.
     
    Signature:/s/ Morgan C. Frank
    Name/Title:Morgan C. Frank
    Date:01/31/2025
    Get the next $ACOG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Havens John Prentiss

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/29/25 4:41:09 PM ET
      $ACOG
    • SEC Form 4 filed by Director Wills Robert James

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:44:29 PM ET
      $ACOG
    • SEC Form 3 filed by new insider Wills Robert James

      3 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:24:20 PM ET
      $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

      1/14/25 8:30:00 AM ET
      $ACOG

    $ACOG
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Alpha Cognition Inc.

      DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)

      4/30/25 4:30:51 PM ET
      $ACOG
    • Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Alpha Cognition Inc. (0001655923) (Filer)

      4/10/25 4:40:34 PM ET
      $ACOG
    • SEC Form 10-K filed by Alpha Cognition Inc.

      10-K - Alpha Cognition Inc. (0001655923) (Filer)

      3/31/25 4:01:52 PM ET
      $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

      H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

      3/18/25 7:48:36 AM ET
      $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

      Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval. "We're excited to share data that underscore ZUNVEYL's potential to deliver meaningful clinical benefit to patients

      4/28/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACOG
    Financials

    Live finance-specific insights

    See more
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

       Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

      3/31/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

      Conference Call Scheduled for March 31, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the lin

      3/19/25 4:30:00 PM ET
      $ACOG